H.C. Wainwright analyst Ed Arce maintained a Buy rating on Aurinia Pharmaceuticals (AUPH) today and set a price target of $15. The company’s shares closed yesterday at $6.08.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 8.5% and a 37.5% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
Aurinia Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $16.50.
See today’s analyst top recommended stocks >>
Based on Aurinia Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $18.34 million. In comparison, last year the company had a GAAP net loss of $13.12 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aurinia Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
